BIOMAT Database Logo BIOMAT Database Logo

[Terguride in the treatment of hyperprolactinemia and acromegaly]. 1986

J Marek, and J Bauer, and J Srámková, and V Hána

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D008090 Lisuride An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS). Lysuride Hydrogen Maleate,Methylergol Carbamide,Arolac,Cuvalit,Dopergin,Dopergine,Lisuride Hydrochloride,Lisuride Maleate,Lisuride Maleate (1:1),Lisuride Maleate, (8beta)-Isomer,Lisuride Mesylate,Lisuride Phosphate (1:1),Lisuride, (8alpha)-(+-)-Isomer,Lysenyl,Lysurid,Revanil,Carbamide, Methylergol,Hydrochloride, Lisuride,Hydrogen Maleate, Lysuride,Maleate, Lisuride,Mesylate, Lisuride
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

J Marek, and J Bauer, and J Srámková, and V Hána
Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.
October 1986, The Journal of clinical endocrinology and metabolism,
J Marek, and J Bauer, and J Srámková, and V Hána
Terguride in the treatment of hyperprolactinemia.
January 1990, Acta Universitatis Palackianae Olomucensis Facultatis Medicae,
J Marek, and J Bauer, and J Srámková, and V Hána
[Terguride in hyperprolactinemia--experiences with 5 patients].
April 1990, Klinische Wochenschrift,
J Marek, and J Bauer, and J Srámková, and V Hána
[Treatment of hyperprolactinemia and acromegaly with lisuride].
June 1989, Harefuah,
J Marek, and J Bauer, and J Srámková, and V Hána
Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
April 1985, Journal of endocrinological investigation,
J Marek, and J Bauer, and J Srámková, and V Hána
[Use of dironyl in the treatment of acromegaly and hyperprolactinemia].
October 1985, Vnitrni lekarstvi,
J Marek, and J Bauer, and J Srámková, and V Hána
[Effectiveness of lysenyl-forte treatment in acromegaly and hyperprolactinemia syndrome].
September 1989, Klinicheskaia meditsina,
J Marek, and J Bauer, and J Srámková, and V Hána
[Drug therapy of hyperprolactinemia and acromegaly].
January 1978, Acta medica Austriaca,
J Marek, and J Bauer, and J Srámková, and V Hána
[Drug therapy of hyperprolactinemia and acromegaly].
May 1983, Schweizerische medizinische Wochenschrift,
J Marek, and J Bauer, and J Srámková, and V Hána
[Combined therapy of acromegaly with a combination of lanreotide and terguride].
November 2000, Casopis lekaru ceskych,
Copied contents to your clipboard!